Achieve Life Sciences Appoints Mark Oki as Chief Financial OfficerAchieve Life Sciences Appoints Mark Oki as Chief Financial Officer

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

2 months ago

SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical…

Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor ConferenceGelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference

Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference

2 months ago

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based…

Safety Shot Announces Online Retail Expansion with one of the US Largest Big Box Store’s E-Commerce PlatformSafety Shot Announces Online Retail Expansion with one of the US Largest Big Box Store’s E-Commerce Platform

Safety Shot Announces Online Retail Expansion with one of the US Largest Big Box Store’s E-Commerce Platform

2 months ago

JUPITER, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“Safety Shot” or “the Company”) today announced…

China’s NMPA Approves EOM’s Coronary Imaging System Based on Conavi Medical’s IPChina’s NMPA Approves EOM’s Coronary Imaging System Based on Conavi Medical’s IP

China’s NMPA Approves EOM’s Coronary Imaging System Based on Conavi Medical’s IP

2 months ago

– Approval triggers fourth and final US$5.9 million milestone payment to Conavi Medical, which it will use to extinguish the…

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on FibrosisaTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

2 months ago

ATYR0101 interacts with LTBP-1 to induce myofibroblast apoptosis through a novel anti-fibrotic mechanism to reduce fibrosis and fibrotic markers in…

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial ArrhythmiaWindtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

2 months ago

WARRINGTON, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company…

BetterLife Announces Favorable Outcome in New York Legal ClaimsBetterLife Announces Favorable Outcome in New York Legal Claims

BetterLife Announces Favorable Outcome in New York Legal Claims

2 months ago

VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU),…

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with AcromegalyCrinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

2 months ago

FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025SAN DIEGO, Dec. 09, 2024 (GLOBE…

Spectral AI Incorporates Frontline Feedback into Improved Software Release for Enhanced Diagnostic PrecisionSpectral AI Incorporates Frontline Feedback into Improved Software Release for Enhanced Diagnostic Precision

Spectral AI Incorporates Frontline Feedback into Improved Software Release for Enhanced Diagnostic Precision

2 months ago

DALLAS, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI)…

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics’ Prolaris® Test as an ‘Advanced Tool’ Recommended for Prognostic AssessmentNCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics’ Prolaris® Test as an ‘Advanced Tool’ Recommended for Prognostic Assessment

NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics’ Prolaris® Test as an ‘Advanced Tool’ Recommended for Prognostic Assessment

2 months ago

Prolaris Remains a Long-Standing Fixture in the Guidelines for 10th Year RunningSALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) --…